2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved response
2019
Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
Luedemann WM, Geisel D, Gebauer B, Schnapauff D, Chapiro J, Wieners G, Steffen I, Kahn J. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT? European Radiology 2019, 30: 1601-1608. PMID: 31811428, DOI: 10.1007/s00330-019-06430-2.Peer-Reviewed Original ResearchMeSH KeywordsArteriesCarcinoma, HepatocellularContrast MediaEthiodized OilFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedTumor BurdenConceptsLipiodol depositionNative CT scansTumor volumeTumour vascularisationTechnical successHCC patientsCE-CTCT scanDifferent imaging modalitiesImaging modalitiesContrast-enhanced CTContrast-enhanced MRPearson correlation coefficientBaseline imagingSubgroup analysisRespective regression coefficientsCT groupLinear regression analysisCE-MRICE-MRVascularisationCTContrast phasesPatientsCTACEFluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapyTheranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model
van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019, 9: 3674-3686. PMID: 31281506, PMCID: PMC6587357, DOI: 10.7150/thno.32943.Peer-Reviewed Original ResearchConceptsOil Red OPerfusion indexMicrovascular densityLipiodol depositionLiver cancerTherapeutic efficacyVX2 tumorsContrast-enhanced CT scanRabbit liver tumor modelTumor-specific functionsNon-tumoral liverLiver tumor modelRadiological-pathological correlationVX2 rabbit liver tumor modelPortal flowTransarterial chemoembolizationLeft lobeLipiodol retentionTherapeutic managementPatient responseTumor vascularityTumor volumeArterial flowCT scanTumor perfusionQuantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization
Schobert I, Chapiro J, Nezami N, Hamm CA, Gebauer B, Lin M, Pollak J, Saperstein L, Schlachter T, Savic LJ. Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization. Journal Of Nuclear Medicine 2019, 60: 1066-1072. PMID: 30655331, PMCID: PMC6681698, DOI: 10.2967/jnumed.118.219691.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiographyBiomarkersCarcinoma, HepatocellularEmbolization, TherapeuticFeasibility StudiesFemaleHumansImaging, Three-DimensionalLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMicrospheresMiddle AgedMultimodal ImagingPrognosisRegression AnalysisRetrospective StudiesTomography, Emission-Computed, Single-PhotonTomography, X-Ray ComputedTreatment OutcomeYttrium RadioisotopesConceptsNon-HCC patientsTransarterial radioembolizationHepatocellular carcinomaBaseline imagingTumor responseTumor volumeChild-Pugh class B patientsBaseline imaging featuresClass B patientsNormal liver ratiosTotal tumor volumeSPECT/CTContrast-enhanced MRIQuantitative European AssociationMultiphasic contrast-enhanced MRIInstitutional review boardHigh TNRPreprocedural MRIChild-PughB patientsLiver criteriaTumor burdenClinical parametersHepatic malignanciesRetrospective study
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases